Evidence-aware
Safety focused
Women’s Health Clinic FAQ
What is intimate polynucleotide therapy?
Intimate polynucleotides are non-hormonal biostimulatory treatments used in some clinics for vulvovaginal tissue quality. The key decision is whether the symptom has been properly assessed first.
Direct answer
Intimate polynucleotide therapy is a non-hormonal injectable treatment using purified DNA fragments to support vulvovaginal tissue hydration, repair signalling and collagen or elastin activity. It is usually discussed for dryness, tissue fragility, dyspareunia or GSM-related concerns. It is not a simple filler and it is not suitable for everyone; infection, bleeding, severe fish allergy, pregnancy, recent surgery and unexplained pain need assessment first.
The safest plan starts by clarifying the symptom, checking red flags, explaining alternatives and agreeing realistic expectations before any procedure is booked.
Educational only. Suitability must be confirmed after consultation and assessment. Results vary. Not a cure.
At a glance
These are the main points to understand before deciding whether this option is suitable.
Polynucleotides at a glance
Non-hormonal biostimulation
Active Ingredients
Polynucleotides (typically derived from salmon or trout DNA), frequently combined with hyaluronic acid (HA) and mannitol (e.g., in the NewGyn®.
Primary Indications
Vaginal dryness, dyspareunia (painful intercourse), chronic itching, irritation, and tissue laxity associated with menopause, aging, or childbirth .
Mechanism
Acts as a bio-stimulator, activating fibroblasts to generate new collagen I and II, improving microcirculation, and retaining moisture at a.
Safety Profile
Extremely biocompatible with low but not absent risk of an immunogenic/allergic response due to the absence of proteins .
Important safety note
Expected Side Effects: Temporary redness, mild swelling, pinpoint bleeding, or small bumps (papules) at the injection sites, which typically resolve within 12 to 72 hours . Bruising may take up to two.
Allergy
Technique
Timeline
Aftercare
Detailed answer
How polynucleotides fit into intimate care
Polynucleotides are best explained as biostimulatory DNA fragments rather than fillers. The clinical question is whether they match the diagnosis, tissue findings and safety profile.
Not a standard filler
The aim is gradual tissue-quality support through repair signalling, hydration and extracellular-matrix activity, not instant volume or a promised sexual-function outcome.
Evidence
Symptoms
Alternatives
What it means
Symptom Relief: A pilot study of 50 postmenopausal women demonstrated statistically reported improvements in Vaginal Health Index (VHI), Vulvar Health Index (VuHI), and Female Sexual Function Index (FSFI) scores following.
Why it happens
Rapid Improvement: Exploratory studies report that symptom scores for itching, irritation, and dyspareunia can drop by roughly 42% to 52% after just two PN priming sessions .
Evidence limits
Clinical Versatility: Polynucleotides present an effective, non-hormonal solution for breast cancer survivors or women who have contraindications against traditional local ooestrogen therapies .
Treatment fit
Setting: Administered in an outpatient or clinical setting by a trained physician or specialist nurse .
What this means in practice
Setting: Administered in an outpatient or clinical setting by a trained physician or specialist nurse .
Procedure Time: Approximately 10 to 30 minutes per session .
Patient safety
Why diagnosis comes first
Dryness, soreness, tearing or painful sex may reflect GSM, infection, dermatoses, pelvic-floor guarding or medication effects, so the treatment choice depends on assessment.
It checks the cause
Symptom Relief: A pilot study of 50 postmenopausal women demonstrated statistically reported improvements in Vaginal Health Index (VHI), Vulvar Health Index (VuHI), and Female.
It protects safety
Expected Side Effects: Temporary redness, mild swelling, pinpoint bleeding, or small bumps (papules) at the injection sites, which typically resolve within 12 to 72.
It reviews alternatives
Setting: Administered in an outpatient or clinical setting by a trained physician or specialist nurse .
It sets expectations
Procedure Time: Approximately 10 to 30 minutes per session .
Non-hormonal does not mean automatic
A hormone-free treatment may still be unsuitable if there is active infection, unexplained bleeding, pregnancy, recent surgery, severe fish allergy or unclear pelvic pain.
The consultation should cover product source, allergy risk, alternatives such as moisturisers or local hormonal care, and realistic timelines for tissue response.
Considerations
What to consider
Setting: Administered in an outpatient or clinical setting by a trained physician or specialist nurse .
Consultation priorities
Consultation: Comprehensive assessment of GSM symptoms, medical history, and confirmation that the patient is a suitable candidate (ruling out infections or red flags) .
Consent
Aftercare
Follow-up
Before treatment
Consultation: Comprehensive assessment of GSM symptoms, medical history, and confirmation that the patient is a suitable candidate (ruling out infections or red flags) .
During care
Procedure Day: The vulvovaginal area is cleansed, numb cream is applied, and tiny intradermal injections are mapped across the mucosal lamina propria and vulvar skin .
Aftercare
Immediate Aftercare: Keep the area clean, avoid touching the injection sites, and utilize cold packs if needed for swelling .
When to reassess
Post-Treatment Restrictions: Patients must abstain from sexual intercourse, hot baths, saunas, and rigorous exercise (like cycling or horseback riding) for 48 to 72 hours .
Practical expectations
Procedure Time: Approximately 10 to 30 minutes per session .
Costs should be confirmed on the /pricing/ page before booking
Common concerns and myths
Common misconceptions
Clear patient information should correct over-simple claims and keep expectations realistic.
Myth: polynucleotides are fillers
Reality: they are biostimulatory DNA fragments, usually used for gradual tissue-quality support rather than volume.
Myth: hormone-free means suitable for everyone
Reality: allergy, infection, bleeding, pregnancy, recent surgery and unexplained pain can still make treatment unsuitable.
Myth: hydration means instant repair
Reality: hydration may be noticed earlier, but collagen and tissue-quality changes are gradual and variable.
Evidence and limits
Mechanism-of-action language should not be treated as proof of a predictable clinical result.
Alternatives still matter
Moisturisers, local hormonal care, pelvic-floor physiotherapy, infection treatment or specialist review may be more appropriate for some patients.
Safety checklist
Safety checklist
Use these questions to decide whether treatment should be discussed, delayed or redirected.
Has the cause been assessed?
Symptoms should be reviewed in context before selecting a treatment.
Are red flags absent?
Do not claim intimate polynucleotides cure dryness, laxity, sexual dysfunction, pelvic symptoms, scarring or menopause-related tissue change. Explain that PN products are often fish/marine-derived and allergy history matters.
Are alternatives clear?
Setting: Administered in an outpatient or clinical setting by a trained physician or specialist nurse .
Is follow-up planned?
The clinic should explain aftercare, review timing and when to seek help.
Reassuring signs
Proceeding is more reasonable when goals are clear, red flags have been checked, and expectations are realistic.
No red flags
Follow-up plan
Reasons to pause
Pause treatment for active infection, unexplained bleeding, severe fish allergy, pregnancy, recent pelvic surgery or severe pain that has not been assessed.
Bleeding
Infection
When to escalate
When to seek medical help
Some symptoms should be assessed before any elective intimate treatment. Use NHS 111 online
Allergy symptoms
Swelling of the lips or tongue, breathing difficulty, widespread hives, faintness or collapse after exposure needs urgent medical help.
Bleeding or infection
New post-menopausal bleeding, unusual discharge, fever, pelvic pain, thrush, BV or UTI symptoms should be assessed before injectable treatment.
Infection signs
Contraindications: Patients should avoid the treatment if they have active genital infections (BV, thrush, UTI), undiagnosed or new post-menopausal bleeding, or if they are recovering from recent pelvic.
Emergency symptoms
Call 999 in a life-threatening emergency, including collapse, chest pain or breathing difficulty.
Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.
Regulatory resources
Authoritative resources
These sources support cautious, assessment-led patient information and help separate clinical evidence from promotional claims.
PubMed: PN/HA intradermal injections for vulvovaginal atrophy
This pilot study is directly relevant to polynucleotide and hyaluronic acid use in vulvovaginal atrophy.
Real-world study of polynucleotide-based vaginal ovules
This source supports cautious discussion of PN-based vaginal ovules, hydration and atrophy-related symptoms.
NHS guidance on allergies
NHS allergy guidance supports screening and urgent escalation language for fish-derived products.
Next step
Book a clinical consultation
A consultation can confirm whether this treatment may be suitable, whether another pathway should come first, and what realistic outcomes, risks and aftercare would look like.
▶ View Research Sources (12 Sources)
These 12 source names are selected from 24 display-ready sources, with a raw audit trail of 51 imported records. Additional reviewed material included peer-reviewed clinical papers, clinical trial records; duplicate, low-relevance and non-clinical records were removed before display.
Educational only. This information is for education only and is not a substitute for professional medical advice, diagnosis or treatment. Results vary. Not a cure.
